Novo Nordisk's obesity drug shows weight loss of up to 14.5% in mid-stage study

Core Insights - Novo Nordisk's experimental obesity drug, amycretin, demonstrated a statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes during a mid-stage study [1] Company Summary - The drug amycretin is currently in mid-stage clinical trials, indicating ongoing development and potential future market introduction [1] - The results from the study highlight the effectiveness of amycretin in addressing obesity, particularly in patients with type 2 diabetes, which could position Novo Nordisk favorably in the obesity treatment market [1]